SCHEMBL3876516

SCHEMBL3876516

COC(=O)c1cc(-c2ccc(SC)cc2)n(-c2ccccc2)n1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RPA1 P27694 3/20 0.56
MALT1 Q9UDY8 2/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
PTGS2 P35354 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
MDM2 Q00987 4/20 0.53
MCL1 Q07820 3/20 0.53
BCL2 P10415 2/20 0.53
FAAH O00519 2/20 0.51
MGLL Q99685 1/20 0.51
CACNA1G O43497 1/20 0.49
CACNA1H O95180 1/20 0.49
PPP1CA P62136 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866686 0.89 SMPD1 (0.56) RPA1MALT1SMN1; SMN2PTGS2PPP1CA
SCHEMBL13239857 0.88 RPA1 (0.70) RPA1MALT1MEN1KMT2ASMN1; SMN2
SCHEMBL3863671 0.88 SMN1; SMN2 (0.69) RPA1MALT1MEN1KMT2ASMN1; SMN2
SCHEMBL3873182 0.88 SMPD1 (0.58) RPA1MALT1SMN1; SMN2PTGS2
SCHEMBL3863714 0.88 RPA1 (0.60) RPA1MALT1MEN1KMT2ASMN1; SMN2
SCHEMBL3865146 0.88 PTGS2 (0.69) RPA1MALT1MEN1KMT2ASMN1; SMN2
SCHEMBL9206389 0.87 CA9 (0.64) RPA1KMT2AL3MBTL1MDM2MCL1
SCHEMBL3870911 0.85 PTGS2 (0.54) MALT1SMN1; SMN2PTGS2FAAH
SCHEMBL3870127 0.85 RPA1 (0.52) RPA1SMN1; SMN2PTGS2
SCHEMBL5151443 0.84 RPA1 (0.51) RPA1MALT1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2009-01-01 US disclosed
US-7442802-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2008-10-28 US disclosed
US-20070155734-A1 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2007-07-05 US disclosed
EP-1539679-A4 OXIME AND/OR HYDRAZONE CONTAINING NITROSATED AND/OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2007-07-04 EP disclosed
US-7211598-B2 Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2007-05-01 US disclosed
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-31 US disclosed
US-7087630-B2 Cyclooxygenase 2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-08 US disclosed
EP-1539679-A2 OXIME AND/OR HYDRAZONE CONTAINING NITROSATED AND/OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-06-15 EP disclosed
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-03-18 US disclosed
WO-2004002420-A2 OXIME AND/OR HYDRAZONE CONTAINING NITROSATED AND/OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2004-01-08 WO disclosed
US-20040006133-A1 Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 RPA1 4494/4885MALT1 3536/4885MEN1 4470/4885
US-20040006133-A1 Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, HMOX1, NOS2 RPA1 4410/4885MALT1 2595/4885MEN1 4605/4885
US-20070155734-A1 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, NOS2, HMOX2 RPA1 4646/4885MALT1 2451/4885MEN1 4341/4885
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 RPA1 4494/4885MALT1 3536/4885MEN1 4470/4885
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE PTGS2, PTGIS, PTGES2 RPA1 4494/4885MALT1 3536/4885MEN1 4470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.